title: [Acute myelomonocytic leukemia with abnormal eosinophils].
abstract: A total of 32 patients with acute myelomonocytic leukemia and abnormal bone marrow eosinophils (LAM4 Eo) have been treated at this Institute since 1977. Abnormalities of chromosome 16 have been noted in 14 of 22 evaluable cases. After a median follow-up of 4 years, median duration of complete remission was 46 months and median duration of survival had not been reached; 8 patients have been receiving no therapy for between 1 and 6 years. These results compare favorably with LAM4 without abnormal bone marrow eosinophils (median duration of complete remission: 12 months; median duration of survival: 14 months). LAM4 Eo constitute a particular entity, with a special hematological presentation, the incidence of abnormalities of chromosome 16, and a particularly good prognosis.
authors.forename: J M
authors.initials: JM
authors.lastname: Extra
authors.forename: M
authors.initials: M
authors.lastname: Marty
authors.forename: F
authors.initials: F
authors.lastname: Calvo
authors.forename: M T
authors.initials: MT
authors.lastname: Daniel
authors.forename: R
authors.initials: R
authors.lastname: Berger
authors.forename: M
authors.initials: M
authors.lastname: Boiron
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D002869:Chromosome Aberrations / Q000235:genetics*; D025063:Chromosome Disorders; D002885:Chromosomes, Human, Pair 16; D004804:Eosinophils / Q000648:ultrastructure*; D005260:Female; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000473:pathology* / Q000628:therapy; D008297:Male; D011379:Prognosis
vernacular_title: La leucémie aiguë myélomonocytaire à éosinophiles anormaux.